The Healthcare Sector in 2024: Opportunities to Consider
2024 is already on the horizon. By December at the latest, investors will be wondering how they should position themselves for the coming year. How interest rates by the major central banks will develop, is not yet clear. It also remains a question whether economies in Europe will slide into recession. In such difficult market situations, defensive sectors that have already successfully faced difficult times on the market in the past are particularly suitable. One example is the healthcare industry. As the sector encompasses reliability and multi-layered growth prospects, it is worth taking a look at the details, even beyond the hype surrounding the injections from Eli Lilly and Novo Nordisk.
Innovations: From gene scissors to new cancer therapies
Demographic factors have always been a classic driver for the healthcare industry - a growing global population requires more medical care. Increasing prosperity in emerging markets is also supporting demand. Currently, however, there are some technological innovations that provide opportunities for investors to support them with investments in pharmaceutical and biotech stocks. Immunotherapy is playing an increasingly important role in the field of cancer research. The aggressive treatment of early stages of cancer in particular, has proven to be successful. Early detection will play an even greater role in the future, in order to better treat aggressive diseases such as pancreatic cancer or myeloid leukemia. Companies with a focus on this development could benefit. The area of diagnostics is also interesting because the Inflation Reduction Act (IRA) has tightened price regulation for certain blockbuster drugs in the USA - investments in oncology have therefore become more complicated.
Nevertheless, innovation remains an important driver of growth in the healthcare industry. The success of mRNA vaccines during the coronavirus pandemic also provides attention to cancer research. Companies such as BioNTech and Moderna have already established research pipelines with a focus on this innovative technology. Numerous lesser-known companies are moreover advancing research or developing auxiliary technologies to optimize the efficacy of new mRNA vaccines. Radiopharmaceuticals, i.e. drugs that contain specific radioactive isotopes and are able to destroy cancer cells, are an exciting future trend. Companies, researching this new technology often target deadly types of cancer. The reason for this is that it is easier to make an argument for added value compared to standard therapies in clinical trials - in acute myeloid blood cancer, for example, clinics still rely on chemotherapy, which had already been the treatment of choice in a similar form, back in the 1960s.